Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

114.31 +12.60 (+12.39%)
Delayed Quote Updated: 10:27 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Haemonetics (HAE) Shares Skyrocket, What You Need To Know
What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 12.4% in the morning session after CSL Plasma announced intentions to complete ... 
Via StockStory
Topics Earnings
Thursday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
Haemonetics (NYSE:HAE): A Quality Investing Candidate Built on Durable Fundamentals ↗
Via Chartmill
News headline image
1 Momentum Stock with Competitive Advantages and 2 We Avoid
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
Via StockStory
Topics Artificial Intelligence
Haemonetics (NYSE:HAE) Shines in Quality Investing Screen ↗
Via Chartmill
News headline image
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
2 Momentum Stocks with Exciting Potential and 1 We Avoid
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
Via StockStory
News headline image
Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Haemonetics (NYSE:HAE) and it... 
Via StockStory
News headline image
1 Russell 2000 Stock with Competitive Advantages and 2 We Turn Down
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou... 
Via StockStory
News headline image
Haemonetics Shares Hit New 52-Week High: What's Happening? ↗
Shares of Haemonetics Corp (NYSE: HAE) are trading higher Tuesday afternoon following news of a significant commercial agreement. 
Via Benzinga
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Haemonetics (HAE) Q1 2027 Earnings Call Transcript ↗
Plasma disposables surged 25% as Persona PLUS adoption accelerated globally. 
Via The Motley Fool
Topics Earnings
News headline image
5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call
Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its ... 
Via StockStory
Topics Earnings
News headline image
Haemonetics Q1 Earnings Call Highlights ↗
Haemonetics (NYSE:HAE) reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The... 
Via MarketBeat
Topics Earnings
News headline image
HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady
Blood products company Haemonetics (NYSE:HAE) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.6% year on year to $339.4 million. Its no... 
Via StockStory
Topics World Trade
News headline image
Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations
Blood products company Haemonetics (NYSE:HAE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.6% year on year to $339.... 
Via StockStory
News headline image
What To Expect From Haemonetics’s (HAE) Q2 Earnings
Blood products company Haemonetics (NYSE:HAE) will be reporting results this Thursday before market open. Here’s what to look for. Haemonetics beat analysts’... 
Via StockStory
News headline image
1 Cash-Producing Stock with Promising Prospects and 2 That Underwhelm
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron... 
Via StockStory
News headline image
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
3 Reasons HAE is Risky and 1 Stock to Buy Instead
Over the last six months, Haemonetics’s shares have sunk to $75.12, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 6.1% gain. This m... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 Profitable Stocks We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Haemonetics (HAE) Stock Is Up, What You Need To Know
What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 4.1% in the afternoon session after BofA Securities upgraded its rating on the ... 
Via StockStory
News headline image
Medical Devices & Supplies - Specialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
News headline image
3 Russell 2000 Stocks That Concern Us
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
Haemonetics Q4 Earnings Call Highlights ↗
Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies... 
Via MarketBeat
Topics Earnings
News headline image
Haemonetics (HAE) Q4 2026 Earnings Transcript ↗
Haemonetics (HAE) Q4 2026 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.